The DOI matches its Crossref record; 146 of the 146 references it cites were found in a registry or an index.
Cancer of the ovary, fallopian tube, and peritoneum: 2021 update
Open accessAbstract
In 2014, FIGO’s Committee for Gynecologic Oncology revised the staging of ovarian cancer, incorporating ovarian, fallopian tube, and peritoneal cancer into the same system. Most of these malignancies are high‐grade serous carcinomas (HGSC). Stage IC is now divided into three categories: IC1 (surgical spill); IC2 (capsule ruptured before surgery or tumor on ovarian or fallopian tube surface); and IC3 (malignant cells in the ascites or peritoneal washings). The updated staging includes a revision of Stage IIIC based on spread to the retroperitoneal lymph nodes alone without intraperitoneal dissemination. This category is now subdivided into IIIA1(i) (metastasis ≤10 mm in greatest dimension), and IIIA1(ii) (metastasis >10 mm in greatest dimension). Stage IIIA2 is now “microscopic extrapelvic peritoneal involvement with or without positive retroperitoneal lymph node” metastasis. This review summarizes the genetics, surgical management, chemotherapy, and targeted therapies for epithelial cancers, and the treatment of ovarian germ cell and stromal malignancies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
Siegel, R. L., Miller, K. D., & Jemal, A. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21590 · Cited by 20,444
Amin, M. B., Greene, F. L., Edge, S. B., Compton, C. C., Gershenwald, J. E., Brookland, R. K., Meyer, L., Gress, D. M., Byrd, D. R., & Winchester, D. P. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21388 · Cited by 6,502
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Moore, K., Colombo, N., Scambia, G., Kim, B.-G., Oaknin, A., Friedlander, M., Lisyanskaya, A., Floquet, A., Leary, A., Sonke, G. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810858 · Cited by 2,870
Self-citationIntraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
Armstrong, D. K., Bundy, B., Wenzel, L., Huang, H. Q., Baergen, R., Lele, S., Copeland, L. J., Walker, J. L., & Burger, R. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052985 · Cited by 2,625
Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer
Vergote, I., Tropé, C. G., Amant, F., Kristensen, G. B., Ehlen, T., Johnson, N., Verheijen, R. H. M., van der Burg, M. E. L., Lacave, A. J., Panici, P. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908806 · Cited by 2,537
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
Mirza, M. R., Monk, B. J., Herrstedt, J., Oza, A. M., Mahner, S., Redondo, A., Fabbro, M., Ledermann, J. A., Lorusso, D., Vergote, I., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1611310 · Cited by 2,451
Self-citationIncorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
Burger, R. A., Brady, M. F., Bookman, M. A., Fleming, G. F., Monk, B. J., Huang, H., Mannel, R. S., Homesley, H. D., Fowler, J., Greer, B. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104390 · Cited by 2,404
Bristow, R. E., Tomacruz, R. S., Armstrong, D. K., Trimble, E. L., & Montz, F. J. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.5.1248 · Cited by 2,312
The Risk of Cancer Associated with Specific Mutations of BRCA1 and BRCA2 among Ashkenazi Jews
Struewing, J. P., Hartge, P., Wacholder, S., Baker, S. M., Berlin, M., McAdams, M., Timmerman, M. M., Brody, L. C., & Tucker, M. A. (1997) · New England Journal of Medicine · doi:10.1056/nejm199705153362001 · Cited by 2,281
Cited by
Caruso, G., Weroha, S. J., & Cliby, W. (2025) · JAMA · doi:10.1001/jama.2025.9495 · Cited by 304
Deciphering the ghost proteome in ovarian cancer cells by deep proteogenomic characterization
Garcia-del Rio, D. F., Derhourhi, M., Bonnefond, A., Leblanc, S., Guilloy, N., Roucou, X., Eyckerman, S., Gevaert, K., Salzet, M., & Cardon, T. (2024) · Cell Death & Disease · doi:10.1038/s41419-024-07046-1 · Cited by 7
Metadata
- Authors
- Berek, J. S., Renz, M., Kehoe, S., Kumar, L., & Friedlander, M.
- Venue
- International Journal of Gynecology & Obstetrics
- Publisher
- Wiley
- Published
- 2021-10
- Volume
- 155
- Issue
- S1
- Pages
- 61-85
- ISSN
- 0020-6695 (ISSN-L)
- 0020-7292
- 1879-3479
- OpenAlex
- W3207350175
- Cited by
- 514
- References
- 146
- FWCI
- 50.71
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cancer of the ovary, fallopian tube, and peritoneum: 2021 update. https://app.cochat.ai/papers/10.1002/ijgo.13878
- The paper
- Berek, J. S., Renz, M., Kehoe, S., Kumar, L., & Friedlander, M. (2021). Cancer of the ovary, fallopian tube, and peritoneum: 2021 update. International Journal of Gynecology & Obstetrics. https://doi.org/10.1002/ijgo.13878
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.